Table IV.

Bleomycin lung toxicity characteristics.

Case	Age (years)/sex	Treatment	Tobacco history (status at entry)	Baseline EF FVC, and DLCO	Timing of BLT	Initial CTCAE code	Death due to BLT	HL disease status
1	72/M	ABVD	46 pack-years (active)	72%, 84%, and 47%	Cycle 5	Grade 3 hypoxia	No	DWOD*
2	61/F	ABVD	None	49%, 66%, and 54%	Cycle 5	Grade 2 SOB	No	DOD
3	66/M	ABVD	40 pack-years (none in 20 years)	55%, 74%, and 84%	Cycle 5	Grade 2 cough	No	AWOD
4	64/F	ABVD	None	45%, 102%, and 87%	Cycle 5	Grade 1 cough, Grade 1 PI	No	AWOD
5	69/M	Stanford V	50-pack years (active)	62%, 89%, and 90%	Month 3	Grade 4 dyspnea	No	AWOD
6	66/M	ABVD	None	67%, 92%, and 24%	Cycle 4	Grade 2 cough	No	AWOD
7	72/F	ABVD	None	78%, 95%, and 83%	Cycle 6	Grade 2 cough	No	AWOD
8	78/F	ABVD	None	73%, 75%, and 77%	Cycle 3	Grade 4 pulmonary	Yes	DWOD^
9	62/F	ABVD	60-pack years (none in 20 years)	NA, 72%, and 63%	Cycle 6	Grade 2 cough	No	AWOD
10	77/F	ABVD	5 pack-years (none in 40 years)	79%, 106%, and 92%	Cycle 4	Grade 1 cough, Grade 1 PI	No	AWOD
11	69/M	ABVD	None	55%, 104%, and 115%	Cycle 3	Grade 3 pulmonary	Yes	DWOD^

Abbreviations: M, male; F, female; FVC, forced vital capacity; DLCO, diffusion of lung capacity of carbon monoxide; EF, ejection fraction; CTCAE, Common Terminology Criteria for Adverse Events; BLT, bleomycin lung toxicity; HL, Hodgkin lymphoma; SOB, shortness of breath; AWOD, alive without disease; DOD, dead as a result of disease; DWOD, dead without disease; PI, pulmonary infiltrates.

^*Death due to lung cancer.

^{^}Death due to acute pulmonary fibrosis (during chemotherapy).